Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression
International Journal of Molecular Medicine · 28.04.2026 · 57 (6) · 1-14
DOI: 10.3892/ijmm.2026.5839 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 28.04.2026. Verfasst von Hang Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Second Hospital Affiliated to Jilin University, Changchun, Jilin 130000, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen, Protein Kinase Inhibitors. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
, gilteritinib inhibited H2228/Al cell growth, induced apoptosis and reduced ALK protein levels. Co‑culture and rescue experiments suggested the mechanism involved inhibiting PD‑L1 and CD8 co‑expression, corroborated by animal experiments. Gilteritinib can overcome alectinib resistance and inhibit PD‑L1 and CD8 co‑expression in ALK‑rearranged NSCLC, providing a new therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Second Hospital Affiliated to Jilin University, Changchun, Jilin 130000, P.R. China.
- Department of Pharmacy, Jilin Cancer Hospital, Changchun, Jilin 130000, P.R. China.
Zitieren
APA
Guo, H., Li, Y., Jin, C., Qi, X., Wang, J., Li, B., & Wang, C. (2026). Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression. International Journal of Molecular Medicine, 57(6), 1-14. https://doi.org/10.3892/ijmm.2026.5839
Vancouver
Guo H, Li Y, Jin C, Qi X, Wang J, Li B, et al. Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression. International Journal of Molecular Medicine. 2026;57(6):1-14. doi:10.3892/ijmm.2026.5839
BibTeX
@article{Guo2026,
author = {Guo, Hang and Li, Yaoji and Jin, Chengyan and Qi, Xiao and Wang, Jincheng and Li, Baofeng and Wang, Chunguang},
title = {Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression},
journal = {International Journal of Molecular Medicine},
year = {2026},
volume = {57},
number = {6},
pages = {1--14},
doi = {10.3892/ijmm.2026.5839}
}
EUVIMED